Biome Australia Gains Access to 328 NZ Pharmacies for Activated Probiotics Launch

Strategic Partnership Unlocks New Zealand Market

Biome Australia Limited (ASX, BIO) has taken a significant leap in its international expansion by securing trading terms with Green Cross Health Limited (NZX, GXH), New Zealand’s leading integrated healthcare provider. This agreement paves the way for Biome’s flagship Activated Probiotics to be introduced into 328 pharmacies nationwide, including the prominent Life Pharmacy and UniChem brands, starting September 2025.

Green Cross Health’s pharmacy network commands a substantial market share, processing 40% of all prescriptions in New Zealand and serving nearly two million loyalty program members. This extensive reach offers Biome immediate access to a broad and engaged consumer base, positioning Activated Probiotics for rapid market penetration.

Integrated Supply Chain and Market Coverage

The partnership builds on Biome’s existing wholesale distribution framework established through its July 2025 collaboration with Propharma, a division of EBOS. This integrated supply chain solution combines Propharma’s robust wholesale capabilities with Green Cross Health’s retail dominance, ensuring efficient product availability across urban and community pharmacy settings.

Life Pharmacy’s 65 premium stores cater to urban professionals seeking health and beauty integration, while UniChem’s 250-plus community pharmacies emphasize clinical expertise and healthcare services. This dual-brand approach allows Biome to target diverse consumer segments effectively.

Capitalizing on Market Trends and Regulatory Advantages

New Zealand’s natural health products market, valued at NZ$300 million and growing at 6.5% annually, is heavily pharmacy-driven, with 75% of sales occurring through professional outlets. This dynamic aligns well with Biome’s strategy of leveraging clinical validation and professional endorsements to differentiate its probiotic offerings.

The country’s regulatory environment classifies probiotics as functional foods under Medsafe oversight, permitting evidence-based health claims supported by clinical trials. Biome’s portfolio, backed by rigorous randomized controlled studies, is well-positioned to benefit from this framework, enhancing credibility among healthcare professionals and consumers alike.

Advancing Vision 27 and Growth Prospects

This expansion is a key component of Biome’s Vision 27 strategy, which aims for at least $75 million in cumulative revenue by FY27. The New Zealand launch complements Biome’s focus on early-stage international markets where clinical differentiation and professional distribution partnerships can establish competitive advantages.

Activated Probiotics, recognized as one of Australia’s fastest-growing practitioner-only probiotic brands, offers condition-specific formulations addressing cholesterol, women’s health, mood, and pediatric needs. The collaboration with Green Cross Health, which is actively expanding its branded pharmacy footprint, aligns perfectly with Biome’s evidence-based approach and clinical validation emphasis.

Biome’s Managing Director Blair Vega Norfolk highlighted the strategic significance of this partnership, emphasizing the synergy between Green Cross Health’s integrated healthcare model and Biome’s clinical product positioning. He anticipates meaningful revenue contributions as the company leverages extensive consumer touchpoints and professional credibility in New Zealand.